A Phase 1 interventional study of Ketamine Hydrochloride and Esketamine in Major Depressive Disorder, sponsored by Medical University of Vienna. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-04.
Sponsored by Medical University of Vienna · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies testing ketamine in Depressive Disorder, Major — 21 open to participants now, 26 under way, 5 of them phase 3. Ketamine · Depressive Disorder, Major.
Among the 89 studies testing ketamine in Depressive Disorder, Major, this one is the 29th largest by planned enrollment, is one of 4 that started in 2020, is one of 15 in phase 1, reaches primary completion later than 1 of the 25 other live ones, and was the 60th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →21 of the 89 studies testing ketamine in Depressive Disorder, Major are open now, in 9 countries. Recruiting first, the newest first:
Joshua Rosenblat · Sites in Canada
Ages 18–70
University of Pennsylvania · Sites in United States
Ages 25–65
Università Vita-Salute San Raffaele · Sites in Italy
Ages 18–70
The Royal's Institute of Mental Health Research · Sites in Canada
Ages 18–65
Mayo Clinic · Sites in United States
Ages 18–65
By country, each count listing its studies:
Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 32 · Phase 3 13 · Phase 4 16
First in 2004; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 65 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 38 across the 89 interventional studies. Of the 48 that completed or were terminated, 29 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 89 have an industry lead sponsor. The 10 most frequent:
Medical University of Vienna is the lead sponsor of 1,111 studies on the registry; 186 are open to participants now.
Medical University of Vienna has 8 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
11 of the studies testing ketamine in Depressive Disorder, Major that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06891300Phase 3The Royal's Institute of Mental Health ResearchUnderstanding and Treating Suicidal Ideation With Ketamine | 2027-03 |
| NCT03573349Mayo ClinicKetamine Associated ACC GABA and Glutamate Change and Depression Remission: | 2026-12 |
| NCT06228391Minneapolis Veterans Affairs Medical CenterKetamine Treatment for PTSD and MDD in TBI | 2026-12 |
| NCT06788249University of PennsylvaniaPilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine | 2026-12-15 |
| NCT06480201Texas A&M UniversityGamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 89 studies testing ketamine in Depressive Disorder, Major, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this randomized, placebo-controlled study is to investigate pharmacodynamic differences between racemic ketamine and esketamine using functional fluorodeoxyglucose ([18F]FDG) positron emission tomography/magnetic resonance imaging (PET/MR)
Pilot study I:
A pilot study with healthy controls will be performed in order to investigate pharmacokinetic behavior and acute behavioral effects of intravenous ketamine infusion.
Pilot study II:
A pilot study including 15 healthy volunteers will be performed in order to optimize scanning procedures. The pilot study follows a randomized, placebo-controlled, double-blind, cross-over study design. After enrollment into the study all subjects will undergo two [18F]FDG PET/CT scans in the course of which they will receive either S-ketamine or placebo during the first scan and the respective other study medication during the second scan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms. In a cross-over study design, esketamine will be administered during the second scan and racemic ketamine during the third scan.
Drug: Ketamine Hydrochloride · Drug: Esketamine · Drug: Placebo
Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms. In a cross-over study design, racemic ketamine will be administered during the second scan and esketamine during the third scan.
Drug: Ketamine Hydrochloride · Drug: Esketamine · Drug: Placebo
In a cross-over study design, esketamine will be administered during the first scan and placebo during the second scan.
Drug: Pilot study II: Esketamine · Drug: Pilot study II: Placebo
intravenous infusion
Also known as: Racemic ketamine (R, S)-Ketamine
intravenous infusion
Also known as: (S)-Ketamine
intravenous infusion
Also known as: saline solution
intravenous infusion
Also known as: (S)-Ketamine
intravenous infusion
Also known as: Saline solution
Change in Cerebral metabolic rate of glucose (CMRGlu)
Change in CMRGlu between each PET/MR scan
Time frame: during PETMR/during 45 minutes of infusion
Change in cerebral blood flow (CBF)
Change in CMRGlu between each PET/MR scan
Time frame: during PETMR/during 45 minutes of infusion
Change in Positive and Negative Syndrome Scale
Minimum: 30, Maximum: 210; higher score indicates worse outcome
Time frame: one hour after infusion to baseline
Change in Brief Psychiatric Rating Scale
Minimum: 18, Maximum: 126; higher score indicates worse outcome
Time frame: one hour after infusion to baseline
Change in Clinician Administered Dissociative States Scale
Minimum: 0, Maximum: 92; higher score indicates worse outcome
Time frame: one hour after infusion to baseline
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2020 (actual). Primary completion is estimated for Mar 2025, 53 months after the start.
Of 49 non-industry phase 1 interventional studies under Depressive Disorder, Major, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 16. This study's planned 53 months is above that.
Counting every sponsor, half of 89 studies reached it within 16 months; a quarter within 5 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ketamine · Esketamine
Medical University of Vienna →